Carbonic Anhydrase Inhibitors suppress platelet procoagulant responses and in vivo thrombosis

Area of Science:

• Biochemistry
• Pharmacology
• Hematology

Background:

• Carbonic anhydrase (CA) inhibitors are clinically established for various conditions.
• Their potential role in modulating thrombosis remains largely unexplored.

Purpose of the Study:

• To investigate if carbonic anhydrase inhibition can serve as an alternative strategy for thrombosis control.
• To elucidate the mechanistic evidence for CA inhibitors as anti-procoagulant and anti-thrombotic agents.

Main Methods:

• Utilized high-resolution dynamic imaging for in vitro and in vivo studies.
• Assessed the effects of acetazolamide and methazolamide on platelet procoagulant responses.
• Employed N-methyl acetazolamide as a control lacking CA inhibitory activity.
• Analyzed rotational thromboelastometry outputs for procoagulant activity changes.

Main Results:

• CA inhibitors (acetazolamide, methazolamide) attenuated intracellular chloride ion entry and suppressed platelet procoagulant responses in vitro.
• These inhibitors demonstrated effectiveness in vivo as anti-thrombotics.
• A non-CA inhibitory analog (N-methyl acetazolamide) did not impact platelet procoagulant response.
• Rotational thromboelastometry did not adequately reflect changes in procoagulant activity.

Conclusions:

• Carbonic anhydrase inhibition presents a promising therapeutic avenue for controlling thrombosis.
• Targeting platelet remodeling via CA blockade offers a novel strategy for managing platelet-driven thrombosis.
• This approach spares essential platelet secretion responses, suggesting a favorable safety profile.